KCTD3

Across TCGA pan-cancer cohorts, KCTD3 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of KCTD3’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where KCTD3 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types KCTD3 is over-expressed in tumor, although a few such as HNSC show the opposite, repressed pattern.

CCRCC, LSCC, and PDAC are the cancer types where KCTD3 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in KCTD3 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	All	III,IV	+0.582	<.001	12	view →
LSCC	Male	II,III,IV	+0.341	<.001	4	view →
PDAC	Male	IV	+0.340	.042	1	view →
HNSC	All	IV	−0.243	.031	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

KCTD3–CCRCC

Open the CCRCC breakdown →